Regulator warns of small risk of serious condition in people having RSV jab
It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over.
However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'.
In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.'
It warned staff to be alert to the signs and symptoms of the syndrome.
It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy.
The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill.
RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays.
The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women.
The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK.
Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints.
There may also be problems breathing and drooping face muscles or trouble swallowing or speaking.
Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo.
This is in the context of over 1.9 million doses of Abrysvo administered, it said.
Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date.
In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
14 hours ago
- Reuters
Health Rounds: RSV can boost seniors' heart risks
July 24 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Older adults hospitalized for respiratory syncytial virus (RSV) face an elevated risk of developing heart failure and a dangerous heart rhythm problem, a Canadian study found. The risk for heart failure was seen even in individuals without a history of heart problems, researchers reported in the Journal of the American Geriatrics Society, opens new tab. The researchers reviewed data on more than 100,000 adults aged 65 and older hospitalized in Ontario between 2011 and 2020 for either RSV, influenza, urinary tract infection, or a fracture. The proportion of patients with a subsequent cardiovascular event was 18.5% after an RSV-related hospitalization, compared to 17.7%, 12.1% and 8.4% after hospitalizations for influenza, urinary tract infection, or fracture, respectively. In comparisons of patients who were closely matched according to demographics and risk factors, heart failure (10%–11%) was the most common outcome for RSV patients, occurring in 10% to 11%. Next most common was the heart rhythm disorder atrial fibrillation, occurring in 5% to 6% of RSV patients. The risk for those outcomes, as well as for heart attack, 'was at least two to three times higher in patients with a pre-existing cardiovascular condition compared to those without,' the researchers also said. 'Our findings reinforce the importance of RSV vaccination in older adults and suggest that monitoring for signs of heart disease following an RSV illness may be pragmatic,' study leader Chris Verschoor of Health Sciences North Research Institute in Sudbury, Ontario, said in a statement. Sending dye through the small intestine to look for blockages has been sparing a significant proportion of patients from needing to undergo surgery, a new study shows. The dye, Gastrografin from Bracco Diagnostics Inc., is administered to symptomatic patients before an X-ray or CT scan so that surgeons can see the location and severity of any so-called adhesive small bowel obstructions. Researchers reviewed nationwide data on more than 20,000 patients with suspected small bowel obstruction managed in two periods - 2012 to 2016, before Gastrografin was widely used for this purpose, and 2019 to 2023, when using Gastrografin to visualize intestinal blockages was a standard of care. They found nearly a 45% decrease in surgeries for small bowel obstruction in the Gastrografin era, from 13,257 to 7,333. Small bowel obstruction accounts for 15% of hospital admissions in the U.S., with about 20% of cases needing surgery to reconstruct the intestine, the researchers said. The resulting healthcare costs total over $3 billion each year. Despite better small bowel obstruction outcomes overall, post-surgery mortality increased from 4.4% to 5.9% after use of the dye became standard, and reoperations within 30 days rose from 4.7% to 6.2% - likely because surgeries were probably more complex in the later era, the researchers said. Gastrografin testing had weeded out patients with relatively mild obstructions who ultimately didn't need surgery, they added. 'Previously, patients who had a relatively mild adhesive small bowel obstruction would have been operated on, as we didn't have an alternative option,' study leader Dr. Robert McLoughlin from the University of Connecticut School of Medicine in Farmington said in a statement. 'This meant that in the post-Gastrografin era, the surgeries were more complex and challenging, hence the increased morbidity and mortality.' Still, because surgeons have gotten better at managing patients after surgery for small bowel obstructions, patients in the Gastrografin group averaged 6 days in the hospital, versus about 10 days for patients treated before the Gastrografin era, the researchers reported in the Journal of Surgical Research, opens new tab. The current study was not designed to prove that any of the outcomes were the result of Gastrografin use, the article pointed out. McLoughlin recalled that during a discussion with a younger colleague about managing small bowel obstructions, he mentioned that when he was in training, surgeons operated 'on a lot more' of these patients. That recollection prompted the current study, he said. (To receive the full newsletter in your inbox for free sign up here)
Reuters
16 hours ago
- Reuters
Breakingviews - GSK revenue hole raises chances of risky M&A move
DUBLIN, July 25 (Reuters Breakingviews) - Emma Walmsley, the boss of 57-billion-pound ($77 billion) GSK (GSK.L), opens new tab, has a conspicuously large financial target: generating over 40 billion pounds of revenue by 2031, opens new tab. Right now, she's well behind pace. Given the drugmaker's track record of buying growth, M&A seems like a likely option to make up for lost time. Shareholders will have to be on the lookout for GSK potentially overpaying. Since Walmsley took the helm of the maker of vaccines and HIV treatments in 2017, opens new tab, the company's forward earnings multiple has collapsed from over 12 to less than eight. Spinning off consumer-focused unit Haleon (HLN.L), opens new tab in 2022, opens new tab has only shone a light on the core pharmaceutical group's problems. Analysts currently reckon GSK will rake in just 34 billion pounds of revenue in 2031, according to forecasts gathered by Visible Alpha, which is 15% less than Walmsley's minimum ambition. One reason is that vaccines, which made up nearly a third of sales in 2024, are potentially under threat from U.S. Health Secretary Robert F. Kennedy Jr., a longtime sceptic of immunisations. Another concern is that Dolutegravir, GSK's star HIV treatment which produced nearly 20% of the company's 31 billion pounds of revenue last year, will lose some patent protection from 2028 in the key U.S. market. Walmsley has claimed that she can replenish the shortfall with future sales from many of the company's 14, opens new tab promising drugs under development. But despite GSK delivering 13 positive late-stage drug trials last year, investors seem more focused on the disappointments. Last week, the group's shares fell nearly 5% after its blood cancer medication Blenrep faced a regulatory setback on safety concerns in the U.S. That all explains the appeal of M&A. Since spinning off Haleon, Walmsley has committed over 6 billion pounds to companies that specialise in everything from vaccines to treatments for cancer, lung and liver disorders. She has more firepower. The company will end 2025 with 12.9 billion pounds of net debt, analysts reckon, which is not much more than the average forecast for 11 billion pounds of EBITDA this year, based on estimates collated by Visible Alpha. One common rule of thumb is that public-market investors only start getting antsy when leverage approaches 3 times EBITDA, implying that Walmsley has 20 billion pounds of headroom for M&A. There are several possible targets. GSK could buy out the 89% of $1.3-billion Wave Life Sciences (WVE.O), opens new tab that it doesn't already own. Another option might be $4 billion obesity drug-focused biotech Viking Therapeutics (VKTX.O), opens new tab, which could bring a foothold in a red-hot market. The risk, however, is that any sellers see GSK as a desperate bidder, leading to a higher asking price. Paying over the odds simply to fill a revenue hole would destroy shareholder value, but it wouldn't be unprecedented in the pharma sector. In GSK's case, it would make an already unhealthy valuation even sicklier. Walmsley's investors will be on high alert. Follow Aimee Donnellan on LinkedIn, opens new tab.
Reuters
a day ago
- Reuters
GSK's blood cancer drug gets EU approval
July 24 (Reuters) - The European Union has approved GSK's (GSK.L), opens new tab drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU regulators approved Blenrep after phase III trials showed the drug, when used in combination with standard treatments, extended progression-free survival and improved overall survival in patients with relapsed or refractory multiple myeloma, GSK said. The approval comes a day after the U.S. Food and Drug Administration extended its review of the drug as a combination treatment for the same illness. The FDA's panel of independent experts had last week recommended against the drug, citing concerns about previously documented risks of eye-related side effects. The EU approval marks the sixth regulatory nod for Blenrep combinations, with applications still under review across all major markets. The drug delivers a cell-killing agent directly to tumour cells while limiting damage to healthy tissue — unlike conventional chemotherapy. Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. It affects the immunity-boosting plasma white blood cells.
